Investegate |CureVac Announcements | CureVac: CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

- Study builds on observational epidemiological study
TÜBINGEN, Germany/ BOSTON, USA - December 21, 2020 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that the first participant in a clinical Phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020. The study aims to evaluate the safety and immunogenicity of CVnCoV administered as a two-dose schedule of 12 µg. The trial follows an epidemiological, non-interventional study conducted with healthcare workers from the University Hospital in Mainz.

Related Keywords

Germany ,Boston ,Massachusetts ,United States ,Sarah Fakih ,Lidia Oostvogels ,University Hospital ,University Medical Center Mainz ,University Hospital Mainz ,University Hospital In Mainz ,Infectious Diseases ,New York Nasdaq ,Vice President ,Vice President Investor ,ஜெர்மனி ,போஸ்டன் ,மாசசூசெட்ஸ் ,ஒன்றுபட்டது மாநிலங்களில் ,சாரா ஃபேகி ,பல்கலைக்கழகம் மருத்துவமனை ,தொற்று நோய்கள் ,புதியது யார்க் நாஸ்டாக் ,துணை ப்ரெஸிடெஂட் ,துணை ப்ரெஸிடெஂட் முதலீட்டாளர் ,